Company Overview and News

to your dashboard

Headline News

How Marijuana Acceptance Is Evolving Globally

It’s fascinating to see how the marijuana landscape around the world has evolved in the last three years. According to Canopy Growth (WEED.TO), Canada, Israel, the Czech Republic, Uruguay, and the Netherlands “established federally legal cannabis access regimes” in 2014. (10-0)

Must-Knows before Investing in the Marijuana Industry

In our recent series Should You Jump on the Marijuana Bandwagon? we briefly touched upon the marijuana industry from an investment perspective. (18-0)

A Look at Insys Therapeutics’ Financial Performance

Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales. This product witnessed a decline in shipments by ~50% in 3Q17 as compared with 3Q16.

What Analysts Recommend for Insys Therapeutics and Peers

Insys Therapeutics (INSY) is a commercial-stage specialty pharmaceutical company headquartered in Chandler, Arizona. The company is focused on developing and commercializing innovative products in the supportive care segment.

The Arrival of Marijuana

In the preceding part of this series, we discussed how the ETF Horizons Marijuana Life Sciences ETF (HMMJ.TO) and MedReleaf (LEAF.TO) only began trading in 2017. But that doesn’t mean that 2017 represents the beginning of the marijuana and cannabis industry.

Should You Jump on the Marijuana Bandwagon?

Lately, the investment community has generated a lot of interest in the marijuana industry, thanks to its legalization for recreational use in California as of January 1, 2018. (18-1)

How to Make Some Green From Marijuana Stocks

2018-01-11 investorplace
As marijuana legalization begins to slowly roll out state by state, it follows that marijuana-based businesses have cropped up, and many are trying their hand in the public markets. It is difficult to maintain an objective view of an investment that is so politically charged sometimes, but we cannot dismiss an entire sector out of hand. So, let’s have a look at what marijuana stocks might be worth considering. (5-1)

Ex-Insys employee seeks ban on mentioning 'opioid crisis' at trial - Channel NewsAsia

2018-01-11 channelnewsasia
A former Insys Therapeutics Inc employee accused of engaging in a scheme to pay medical practitioners kickbacks to prescribe a fentanyl-based treatment is seeking to bar U.S. prosecutors from referring to the "opioid crisis" at his trial.

No Immunity For The Massachusetts Marijuana Industry

2018-01-11 seekingalpha
U.S. Attorney General Jeff Sessions decided to rescind federal protections for those operating within state-sanctioned cannabis industries. (6-1)

4 Best Marijuana Stocks to Play the Green Rush

2018-01-09 zacks
Whether its eating a gooey, chocolatey brownie or taking a few hits off a freshly rolled joint, it’s common knowledge that a lot of people like to get high. Many investors, however, have yet to “light up.” Some hesitate from adding marijuana stocks to their portfolio on apprehensions that pot companies are involved in scams or that it’s still deemed illegal by the federal government. (96-1)

California Cannabis Rush May Not Bring A Fortune For Stock Investors

2018-01-06 seekingalpha
The California Gold Rush of 1848 brought fame and fortune to a select few and trouble for many. Recreational cannabis may do the same. It was legalized in California as of 1st January. It will almost certainly be legal in Canada this coming July. This presents many traps for the unwary investor. The history of Growlife (OTCPK:PHOT) is an example of this. (31-0)

Cannabis stocks tank on report DoJ to rescind state protections - MarketWatch

2018-01-04 marketwatch
AG Jeff Sessions expected to announce decision later Thursday that will impact states that have legalized marijuana (13-0)

U.S. Pot ETF's Assets Soar as Investors Rush Into Sector - Bloomberg

2018-01-03 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (25-4)

Your Daily Pharma Scoop: Portola BLA Review Process Delayed, DelMar Soars, Alexion Gets Nod For Soliris In Japan

2017-12-28 seekingalpha
Today we will discuss the implications of the delay in the review of Portola’s (PTLA) AndexXa BLA. The news sent PTLA shares down more than 10% on Tuesday. (31-3)

CUSIP: 45824V209